. Author manuscript; available in PMC: 2020 Oct 3.

Published in final edited form as: Cell. 2019 Sep 26;179(2):312–339. doi: 10.1016/j.cell.2019.09.001

Table 2.

Active phase 3 disease-modifying drug trials in AD

Drug	Study Population	Target	Type of molecule	Status
Gantanerumab	Very mild to mild AD	Conformational epitope found only on fibrillar AD	Monoclonal antibody	Phase 3 enrolling
BAN2401 (CLARITY)	Very mild to mild AD with positive amyloid biomarkers	Aβ protofibrils	Monoclonal antibody	Phase 3 enrolling
Elenbecestat (MISSION-AD1/2)	Mild AD	BACE1 inhibitor	Small molecule	Phase 3 enrolling
ALZT-OP1 (cromolyn sodium/ibuprofen)	Very mild AD with positive CSF amyloid	Anti-inflammatory	Small molecule	Phase 3 enrolling
Levetiracetam	Very mild AD with positive amyloid PET imaging	SV2A	Small molecule	Phase 3 enrolling
CAD106	Cognitively normal ApoE ε4/ε4 homozygotes	Active immunization with Aβ1-6 peptide fused to virus-like particles	Immunogen	Phase 3 no longer enrolling; API Generation primary prevention study
COR388	Mild to moderate AD	Periodontal bacteria gingipain inhibitor	Small molecule	Phase 3 enrolling
AVANEX 2-73	Very early to mild AD with positive amyloid biomarkers	Sigma-1 protein agonist	Small molecule	Phase 3 enrolling